Mr. Darryl Drake reports

VECTOR SCIENCE & THERAPEUTICS APPOINTS DARRYL DRAKE JR. AS PRESIDENT OF VALOR

Vector Science and Therapeutics Corp. has appointed Darryl Drake Jr. as president of Valor and chairman of the athletic board of directors. Valor is a newly formed division of Vector, focused on developing relationships in the professional and elite athlete market and building the commercial infrastructure to support Vector's advancing transdermal peptide delivery platform.

Mr. Drake will lead Valor's market development efforts, initially promoting Vector's line of pharmaceutical-grade peptides, manufactured under cGMP standards in a U.S. Federal Drug Administration-licensed facility and tested to the highest standards for safety and purity, while establishing a network of sports medicine clinicians, trainers and elite athlete advocates ahead of the Valor transdermal delivery platform's commercial launch. Mr. Drake brings more than a decade of leadership building high-performance commercial teams across multiple countries, with a record of managing relationships with top athlete influencers and multimedia-driven platforms that positions him well for the relationship-first mandate Valor requires.

Valor's initial commercial focus is Vector's line of pharmaceutical-grade peptides, manufactured under cGMP standards in an FDA-licensed, state-of-the-art facility in Mequon, Wisconsin and tested to the highest standards for safety, purity and potency. The division is designed to integrate Vector's advances in peptide science with its delivery platforms, creating a combined approach to tissue repair, recovery and pain mitigation that gives clinicians and athletes an alternative to systemic pain medicines, including opiates.

Valor, the sports medicine division of Vector Science and Therapeutics, is purpose-built to develop relationships in the professional athlete market and build the distribution channel for Vector's transdermal peptide delivery platform. Valor's approach targets tissue repair, accelerated recovery and site-directed pain mitigation, drawing on Vector's pharmaceutical-grade peptide portfolio and cGMP manufacturing capabilities in Mequon, Wis.

About Vector Science and Therapeutics Corp.

Vector Science, headquartered in Mequon, Wis., develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable.